A randomized phase II study of gemcitabine plus S-1 versus gemcitabine alone in patients with unresectable pancreatic cancer.

被引：0

作者：

Omuro, Y.

Ikari, T.

Ishii, H.

Ozaka, M.

Suyama, M.

Matsumura, Y.

Itoi, T.

Egawa, N.

Yano, S.

Hanada, K.

Kimura, Y.

Ukita, T.

Ishida, Y.

Tani, M.

Ohoka, S.

Hirose, Y.

Hijioka, S.

Watanabe, R.

Ikeda, T.

Nakajima, T.

机构：

[1] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan

[2] Tobu Chiiki Hosp, Tokyo, Japan

[3] Canc Inst Hosp, Tokyo, Japan

[4] Canc Inst Hosp, Dept Med Oncol, Tokyo, Japan

[5] Juntendo Univ Hosp, Tokyo, Japan

[6] Tokyo Med Univ, Tokyo 1608402, Japan

[7] Kanazawa Univ, Kanazawa, Ishikawa, Japan

[8] JA Onomichi Gen Hosp, Hiroshima, Japan

[9] Sapporo Med Univ Hosp, Sapporo, Hokkaido, Japan

[10] Toho Univ, Ohashi Med Ctr, Tokyo, Japan

[11] Kurume Univ Hosp, Kurume, Fukuoka, Japan

[12] Wakayama Med Univ Hosp, Wakayama, Japan

[13] Tokyo Med & Dent Univ Hosp, Tokyo, Japan

[14] Fukui Red Cross Hosp, Fukui, Japan

[15] Kumamoto Red Cross Hosp, Kumamoto, Japan

[16] Matsuyama Shimin Hosp, Matsuyama, Japan

[17] Yokosuka Kyosai Hosp, Yokosuka, Kanagawa, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4029

引用

下载

页数：1

共 50 条

[11] Randomized phase II study comparing S-1 plus Leucovorin (SL) versus S-1 alone in patients with gemcitabine-refractory advanced pancreatic cancer (APC)
Okusaka, T.
Ueno, M.
Omuro, Y.
Isayama, H.
Fukutomi, A.
Ikeda, M.
Mizuno, N.
Fukuzawa, K.
Hyodo, I.
Boku, N.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S611 - S611
[12] A randomized phase II trial of adjuvant chemotherapy with S-1 versus S-1 and gemcitabine (GS) versus gemcitabine alone (GEM) in patients with resected pancreatic cancer (CAP-002 study).
Yoshitomi, Hideyuki
Shimizu, Hiroaki
Yoshidome, Hiroyuki
Ohtsuka, Masayuki
Kato, Atsushi
Furukawa, Katsunori
Takayashiki, Tsukasa
Kuboki, Satoshi
Okamura, Daiki
Suzuki, Daisuke
Nakajima, Masayuki
Aida, Toshiaki
Miyazaki, Masaru
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[13] Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study)
Ozaka, Masato
Matsumura, Yuji
Ishii, Hiroshi
Omuro, Yasushi
Itoi, Takao
Mouri, Hisatsugu
Hanada, Keiji
Kimura, Yasutoshi
Maetani, Iruru
Okabe, Yoshinobu
Tani, Masaji
Ikeda, Takaaki
Hijioka, Susumu
Watanabe, Ryouhei
Ohoka, Shinya
Hirose, Yuki
Suyama, Masafumi
Egawa, Naoto
Sofuni, Atsushi
Ikari, Takaaki
Nakajima, Toshifusa
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1197 - 1204
[14] Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study)
Masato Ozaka
Yuji Matsumura
Hiroshi Ishii
Yasushi Omuro
Takao Itoi
Hisatsugu Mouri
Keiji Hanada
Yasutoshi Kimura
Iruru Maetani
Yoshinobu Okabe
Masaji Tani
Takaaki Ikeda
Susumu Hijioka
Ryouhei Watanabe
Shinya Ohoka
Yuki Hirose
Masafumi Suyama
Naoto Egawa
Atsushi Sofuni
Takaaki Ikari
Toshifusa Nakajima
Cancer Chemotherapy and Pharmacology, 2012, 69 : 1197 - 1204
[15] A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer
Do-Youn Oh
Yongjun Cha
In-Sil Choi
So-Young Yoon
In Keun Choi
Jee Hyun Kim
Sang Cheul Oh
Chang Duck Kim
Jae Sun Kim
Yung-Jue Bang
Yeul Hong Kim
Cancer Chemotherapy and Pharmacology, 2010, 65 : 527 - 536
[16] Randomized phase II study of the efficacy and safety of gemcitabine plus TH-302 versus gemcitabine alone in previously untreated patients with advanced pancreatic cancer.
Borad, M. J.
Sigal, D.
Uronis, H.
Stephenson, J.
Bahary, N.
Rarick, M. U.
DeMarco, L. C.
Finnegan, T. J.
Chiorean, E. G.
Ryan, D. P.
Cohn, A. L.
Ulrich, B. K.
Harish, V. C.
Anderes, E. N.
Ma, W. W.
Yu, P. P.
Sinicrope, F.
Eng, C.
Sunkara, U. K.
Reddy, S. G.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[17] A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
Scott, Aaron James
O'Neil, Bert H.
Gomes, Christina
Baranda, Joaquina Celebre
Cohen, Steven J.
Tejani, Mohamedtaki Abdulaziz
Maguire, Robert T.
Wilhelm, Francois
Maniar, Manoj
Cohen, Deirdre Jill
Ma, Wen Wee
Aisner, Dara
Cho, Jonathan K.
Olowokure, Olugbenga Olanrele
Coveler, Andrew L.
Menter, Alex R.
Rubin, Peter
Cusnir, Mike
Messersmith, Wells A.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
[18] A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer
Oh, Do-Youn
Cha, Yongjun
Choi, In-Sil
Yoon, So-Young
Choi, In Keun
Kim, Jee Hyun
Oh, Sang Cheul
Kim, Chang Duck
Kim, Jae Sun
Bang, Yung-Jue
Kim, Yeul Hong
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (03) : 527 - 536
[19] Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine-refractory pancreatic cancer
Mizuno, Nobumasa
Yamao, Kenji
Komatsu, Yoshito
Munakata, Masaki
Ishiguro, Atsushi
Yamaguchi, Taketo
Ohkawa, Shinichi
Kida, Mitsuhiro
Ioka, Tatsuya
Takeda, Koji
Kudo, Toshihiro
Kitano, Masayuki
Iguchi, Haruo
Tsuji, Akihito
Ito, Tetsuhide
Tanaka, Masao
Furuse, Junji
Hamada, Chikuma
Sakata, Yuh
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
[20] Phase I/II study of gemcitabine plus S-1 with concurrent radiotherapy in patients of unresectable locally advanced pancreatic cancer
Ioka, Tatsuya
Katayama, Kazuhiro
Ishida, Nobuko
Sueyoshi, Hironari
Takada, Ryoji
Yamai, Takuo
Fukutake, Nobuyasu
Ashida, Reiko
Akita, Hirofumi
Takahashi, Hidenori
Kawaguchi, Yoshifumi
Konishi, Koji
Teshima, Teruki
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)

← 1 2 3 4 5 →